A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema

Inclusion Criteria

• •Adult males and females \> 18 years.
• •Subjects who currently have allergic eczema with an EASI score in the range of 10-50.
• •Subjects who have been on a stable dose of topical medications for eczema for ≥ 1 month from screening but whose eczema is not adequately responsive to, or controlled by, conventional topical treatments (eg: topical steroids, Tracrolimus, Pimecrolimus).
• •Subjects who have not had systemic immunosuppressive therapy (eg systemic steroids) within 1 month of screening.
• •Subjects who if female, are not currently pregnant or breast feeding and are using medically acceptable methods of contraception.
• •Subjects who have a pre-study medical history, physical examination and vital signs acceptable to the investigator.
• •Subjects who have clinical laboratory tests within the reference ranges or clinically acceptable to the investigator.
• •Subjects who are negative for HbsAg, hepatitis C antibody and HIV II and I test at screening.
• •Subjects who are negative for drugs of abuse tests at screening and admission.
• •Subjects with stable, adequately treated medical conditions other than eczema may be enrolled provided the Investigator does not consider their study participation to place them at increased risk of adverse events. Subjects should continue their concomitant treatments for medical conditions (other than eczema).
• +15 more criteria